An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced its participation in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022. The company, focused on developing treatments for neurological disorders and kidney diseases, will hold one-on-one meetings with investors during the virtual event. DiaMedica's lead candidate, DM199, is a recombinant form of the human tissue kallikrein-1 protein, aimed at treating acute ischemic stroke and chronic kidney disease. For more information, visit www.diamedica.com.
Positive
None.
Negative
None.
MINNEAPOLIS--(BUSINESS WIRE)--
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that it will be participating in the 19th Annual Craig-Hallum Institutional Investor Conference being held virtually on Wednesday, June 1, 2022. Management will be available to participate in one-on-one meetings. Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Craig-Hallum representative to arrange a meeting.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant form of the human tissue kallikrein-1 protein (KLK1), an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.
What is the significance of DiaMedica Therapeutics participating in the Craig-Hallum Institutional Investor Conference?
DiaMedica Therapeutics' participation enhances its visibility among investors and highlights its clinical-stage advancements in neurological and kidney disease treatments.
When is the Craig-Hallum Institutional Investor Conference taking place?
The 19th Annual Craig-Hallum Institutional Investor Conference is scheduled for June 1, 2022.
What is DM199 and its purpose?
DM199 is DiaMedica's lead candidate, a recombinant form of the human tissue kallikrein-1 protein designed for treating acute ischemic stroke and chronic kidney disease.
How can investors schedule a meeting with DiaMedica's management during the conference?
Investors interested in meeting DiaMedica's management can contact their Craig-Hallum representative to arrange a meeting.
What therapeutic areas does DiaMedica focus on?
DiaMedica Therapeutics focuses on developing treatments for neurological disorders and kidney diseases.
